-
Dr. Biao Zhu: Common Comorbidities in HIV Patients and Their Antiretroviral Therapy
Although antiretroviral therapy (ART) has greatly reduced the mortality associated with HIV, the morbidity of non-AIDS-related complications associated with HIV remains high. Therefore, it is crucial to understand and assess clinical decision factors for adjusting ART in the context of suppressed HIV RNA. At the recently concluded 12th International AIDS Society HIV Science Conference (…
-
Dr. Yong-an Ye ‘s Team: Using Machine Learning-Based Predictive Models to Identify Early Virological Recurrence Risk in Chinese Chronic Hepatitis B Patients After Entecavir Discontinuation
Currently, most chronic hepatitis B (CHB) patients cannot achieve a cure. While guidelines suggest that some CHB patients can discontinue nucleos(t)ide analogs (NAs) after consolidation therapy, virological recurrence remains common.…
-
Dr. Ana Hoxha: Clinical characteristics and outcomes of MPXV and HIV co-infected patients
In 2022, about 70 countries/regions around the world reported cases of MPOX. These countries/regions usually have no prior history of MPXV infections, and previous sustained human-to-human transmissions of MPXV were mainly observed in Africa. At the recent 12th International AIDS Society HIV Science Conference (IAS 2023), Dr. Ana Hoxha from the World Health Organization (WHO)…
-
De-escalation and Escalation Treatment of Early Breast Cancer—Insights from an Interview with Giuseppe Curigliano at SGBCC 2023
The 18th St. Gallen International Breast Cancer Conference 2023 held in Vienna provided a platform for experts in the field to share their perspectives on the management of early breast cancer. Among the distinguished attendees was Professor Giuseppe Curigliano from the European Institute of Oncology, IRCCS, Milan, Italy. In the interview by Oncology Frontier, he…
-
SGBCC International Dialogue| Dr. Li Zhu & Dr. Giuseppe Curigliano Discuss the Need for Adjuvant Therapy After Achieving pCR in Neoadjuvant Treatment
Neoadjuvant therapy has become an integral part of breast cancer treatment, with its increasing application in clinical practice. However, improving the effectiveness of neoadjuvant therapy and optimizing subsequent treatment strategies is a complex issue to consider. At the 18th St.Gallen Breast Cancer Conference (SGBCC 2023), a debate titled “If you achieve pCR after neoadjuvant, do…
-
SGBCC 2023 | Academician Binghe Xu: Breast Cancer Treatment and Research – An Asian Perspective
The 18th St.Gallen International Breast Cancer Conference (SG-BCC 2023) was held in Vienna, the “City of Music,” from March 15 to 18, 2023. Academician Binghe Xu from the Cancer Hospital of the Chinese Academy of Medical Sciences delivered a presentation titled “Breast Cancer Treatment and Research – An Asian Perspective” during the “Session 10: Global…
-
Dr. Jian Zhang Discusses with Dr. Harbeck: Is Chemotherapy Necessary for ER+/HER2- Breast Cancer Patients with Low Genetic Risk but High Clinical Risk
The 18th St. Gallen International Breast Cancer Conference (SG-BCC 2023) was held in Vienna, the “City of Music,” from March 15 to 18, 2023. Breast cancer experts from around the world gathered at this conference to discuss the most cutting-edge and controversial topics in the diagnosis and treatment of early-stage breast cancer, leading to the…
-
Dr. Jia Wang & Dr. William Gradishar: Controversies in Surgical Treatment for Stage IV Breast Cancer Patients at Initial Diagnosis
There is currently a lack of consensus on whether surgical treatment should be performed for patients with stage IV breast cancer at the initial diagnosis. At the 18th St.Gallen Breast Cancer Conference (SGBCC 2023), a debate titled “Surgery of the primary for stage IV disease” garnered global expert attention. The debate was moderated by Dr.…
Connecting Medical Expertise through Media